Trials / Terminated
TerminatedNCT06299163
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Numab Therapeutics AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Conditions
- Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Peritoneal Carcinoma
- Endometrial Cancer
- Adenocarcinoma of Lung
- Triple Negative Breast Cancer
- Liposarcoma
- Leiomyosarcoma
- Mesothelioma, Malignant
- Adenocarcinoma - Gastroesophageal Junction (GEJ)
- Adenocarcinoma of the Stomach
- Melanoma, Malignant
- Renal Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NM32-2668 | Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-04-18
- Completion
- 2025-04-18
- First posted
- 2024-03-07
- Last updated
- 2025-07-23
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06299163. Inclusion in this directory is not an endorsement.